{"DataElement":{"publicId":"5369046","version":"1","preferredName":"Treatment Cohort Study 9681 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9681 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9681_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5369029","version":"1","preferredName":"9681 Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"5369029v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"250","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"DL7","valueDescription":"DL7: Cycles 1-4(q21d): XL184 60 mg PO QD, MDX-1106 3 mg/kg IV over 60 min on d1; MDX-TRAN 1 mg/kg IV over 90 min on d1: Cycles 5-25 (q28d): XL184 60 mg PO QD, MDX-1106 3 mg/kg IV over 60 min on d1 and 15; Cycles 26+ (q28d): XL184 60 mg PO QD","ValueMeaning":{"publicId":"5369051","version":"1","preferredName":"DL7: Cycles 1-4(q21d): XL184 60 mg PO QD, MDX-1106 3 mg/kg IV over 60 min on d1; MDX-TRAN 1 mg/kg IV over 90 min on d1: Cycles 5-25 (q28d): XL184 60 mg PO QD, MDX-1106 3 mg/kg IV over 60 min on d1 and 15; Cycles 26+ (q28d): XL184 60 mg PO QD","longName":"5369051","preferredDefinition":"DL7: Cycles 1-4(q21d): XL184 60 mg PO QD, MDX-1106 3 mg/kg IV over 60 min on d1; MDX-TRAN 1 mg/kg IV over 90 min on d1: Cycles 5-25 (q28d): XL184 60 mg PO QD, MDX-1106 3 mg/kg IV over 60 min on d1 and 15; Cycles 26+ (q28d): XL184 60 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39042A75-1329-0BEA-E050-BB89AD436114","latestVersionIndicator":"Yes","beginDate":"2016-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-08-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39042A75-1342-0BEA-E050-BB89AD436114","beginDate":"2016-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-08-01","modifiedBy":"ONEDATA","dateModified":"2016-08-01","deletedIndicator":"No"},{"value":"DL8","valueDescription":"DL8: CY 1-4: Cabo 40mg PO QD, Nivo 1mg/kg d1; Ipil 3mg/kg IV d1: CY 5-25: Cabo 40mg PO QD, Nivo 1mg/kg d1&15; CY 26+: Cabo 40mg PO QD & Nivo 480mg d1;Re-Challenge Post-Prog CY 1-4 Cabozantinib 40mg PO QD, Nivo 3mg/kg d1 & Ipil 1mg/kg d1","ValueMeaning":{"publicId":"5827950","version":"1","preferredName":"DL8: CY 1-4: Cabo 40mg PO QD, Nivo 1mg/kg d1; Ipil 3mg/kg IV d1: CY 5-25: Cabo 40mg PO QD, Nivo 1mg/kg d1&15; CY 26+: Cabo 40mg PO QD & Nivo 480mg d1;Re-Challenge Post-Prog CY 1-4 Cabozantinib 40mg PO QD, Nivo 3mg/kg d1 & Ipil 1mg/kg d1","longName":"5827950","preferredDefinition":"DL8: CY 1-4: Cabo 40mg PO QD, Nivo 1mg/kg d1; Ipil 3mg/kg IV d1: CY 5-25: Cabo 40mg PO QD, Nivo 1mg/kg d1&15; CY 26+: Cabo 40mg PO QD & Nivo 480mg d1;Re-Challenge Post-Prog CY 1-4 Cabozantinib 40mg PO QD, Nivo 3mg/kg d1 & Ipil 1mg/kg d1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FA6993E-66F4-5AFB-E053-F662850AE129","latestVersionIndicator":"Yes","beginDate":"2017-05-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-05-16","modifiedBy":"SOKKERL","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FA6993E-670D-5AFB-E053-F662850AE129","beginDate":"2017-05-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-05-16","modifiedBy":"ONEDATA","dateModified":"2017-05-16","deletedIndicator":"No"},{"value":"DL2","valueDescription":"DL2: Cycles 1-21: Cabozantinib 40mg PO QD; Nivolumab 3mg/kg IV days 1 & 15; Cycles 22+: Cabozantinib 40mg PO QD; Re-Challenge Post-Prog Cycles 1-4 Cabozantinib 40mg PO QD, Nivolumab 3mg/kg IV days 1 & Ipilimumab 1mg/kg IV d1","ValueMeaning":{"publicId":"5369030","version":"1","preferredName":"DL2: Cycles 1-21: Cabozantinib 40mg PO QD; Nivolumab 3mg/kg IV days 1 & 15; Cycles 22+: Cabozantinib 40mg PO QD; Re-Challenge Post-Prog Cycles 1-4 Cabozantinib 40mg PO QD, Nivolumab 3mg/kg IV days 1 & Ipilimumab 1mg/kg IV d1","longName":"5369030","preferredDefinition":"DL2: Cycles 1-21: Cabozantinib 40mg PO QD; Nivolumab 3mg/kg IV days 1 & 15; Cycles 22+: Cabozantinib 40mg PO QD; Re-Challenge Post-Prog Cycles 1-4 Cabozantinib 40mg PO QD, Nivolumab 3mg/kg IV days 1 & Ipilimumab 1mg/kg IV d1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39040D07-A07A-D116-E050-BB89AD431F24","latestVersionIndicator":"Yes","beginDate":"2016-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-08-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EB3DB23-A97E-7C32-E053-F662850ABA7C","beginDate":"2016-08-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-04","modifiedBy":"ONEDATA","dateModified":"2017-05-04","deletedIndicator":"No"},{"value":"DL6","valueDescription":"DL6: Cycles 1-4 Cabo 40mg PO QD,Nivo 3mg/kg d1, Ipil 1mg/kg d1: Cycles 5-25 Cabo 40mg PO QD, Nivo 3 mg/kg d1&15; Cycles 26+ Cabo 40mg PO QD, Nivo 480mg d1. Re-Challenge Post-Prog Cycles 1-4 Cabo 40mg PO QD, Nivo 3mg/kg d1 & Ipil 1mg/kg d1","ValueMeaning":{"publicId":"5610023","version":"1","preferredName":"DL6: Cycles 1-4 Cabo 40mg PO QD,Nivo 3mg/kg d1, Ipil 1mg/kg d1: Cycles 5-25 Cabo 40mg PO QD, Nivo 3 mg/kg d1&15; Cycles 26+ Cabo 40mg PO QD, Nivo 480mg d1. Re-Challenge Post-Prog Cycles 1-4 Cabo 40mg PO QD, Nivo 3mg/kg d1 & Ipil 1mg/kg d1","longName":"5610023","preferredDefinition":"DL6: Cycles 1-4 Cabo 40mg PO QD,Nivo 3mg/kg d1, Ipil 1mg/kg d1: Cycles 5-25 Cabo 40mg PO QD, Nivo 3 mg/kg d1&15; Cycles 26+ Cabo 40mg PO QD, Nivo 480mg d1. Re-Challenge Post-Prog Cycles 1-4 Cabo 40mg PO QD, Nivo 3mg/kg d1 & Ipil 1mg/kg d1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44409CF2-9A53-4F9B-E053-F662850A4237","latestVersionIndicator":"Yes","beginDate":"2016-12-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-12-22","modifiedBy":"SOKKERL","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EB3FFF8-687C-7578-E053-F662850AFD1B","beginDate":"2016-12-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-04","modifiedBy":"ONEDATA","dateModified":"2017-05-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4386398","version":"1","preferredName":"Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic.:A system of numbered categories for representation of data.","longName":"C61512:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE558C16-1C27-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"ONEDATA","dateModified":"2014-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39040D07-A063-D116-E050-BB89AD431F24","latestVersionIndicator":"Yes","beginDate":"2016-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-08-01","modifiedBy":"SOKKERL","dateModified":"2019-01-17","changeDescription":"7/19/16 tt, curated for 9681.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Please select the cohort","type":"Preferred Question Text","description":"Please select the cohort","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39042A75-1307-0BEA-E050-BB89AD436114","latestVersionIndicator":"Yes","beginDate":"2016-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-08-01","modifiedBy":"SOKKERL","dateModified":"2017-07-26","changeDescription":"8/1/2016 tt, curated for 9681.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}